Australian authorities granted Hainan Shuangcheng Pharmaceuticals (SHE:002693) marketing authorization for its arginine vasopressin injection.
The drug is indicated for postoperative abdominal distension, removal of interfering gas shadows in abdominal X-ray examinations, and diabetes insipidus treatment, according to a Saturday filing with the Shenzhen bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments